National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 2 of 1998)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves to establish and regulate the framework for national health policies and services. This legislation was introduced to address the need for a comprehensive system to ensure the provision of health services, including pharmaceutical benefits, across the country. One of its significant components is the regulation of pharmaceutical benefits, which includes the authority to determine which drugs and medicinal preparations are eligible for subsidies under the Pharmaceutical Benefits Scheme (PBS). The 1998 legislative instrument, PB 2 of 1998, further refines this framework by specifying certain drugs and medicinal preparations that will no longer be subject to the provisions of Part VII of the Act. This instrument aims to streamline the PBS by removing substances that are no longer considered necessary or effective for subsidised treatments, thereby enhancing the efficiency and efficacy of the national health expenditure.

Scope and Application

The National Health Act 1953, as amended by this legislative instrument, pertains to the Pharmaceutical Benefits Schedule, which regulates the availability and funding of prescription medicines in Australia. This particular Declaration applies to specific drugs and medicinal preparations listed in the Schedule, removing them from the coverage under Part VII of the National Health Act 1953. The Act applies to these specified substances and is in effect for the Commonwealth of Australia, thereby affecting the pharmaceutical industry and healthcare providers across the nation. The legislative instrument provides a definitive list of drugs that are no longer subject to the Pharmaceutical Benefits Scheme, impacting their funding and availability within Australia. The exclusion of these substances from the Pharmaceutical Benefits Schedule is effective from 1 February 1998, and the scope of the Act is further defined through the Schedule, which lists the specific drugs affected by this legislative change.

Key Provisions

The primary sections of this legislative instrument are section 2 and the Schedule (sections 1 and 2). Section 2 states that the drugs and medicinal preparations specified in the Schedule will cease to be subject to Part VII of the National Health Act 1953. The Schedule lists the specific drugs and preparations affected by this cessation. This legislative instrument, therefore, formally removes the listed pharmaceuticals from the Pharmaceutical Benefits Scheme (PBS), meaning they will no longer be subsidised under the PBS from the date of operation, 1 February 1998. The obligations imposed by this legislative instrument primarily concern the entities and individuals managing and administering the National Health Act 1953. Under section 2, these entities and individuals must ensure that the drugs and preparations listed in the Schedule are no longer considered under the PBS from the operation date. This means that they must update their records, systems, and communications to reflect this change. Furthermore, the declaration process, as outlined in subsection 85(2AA), requires the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Family Services to obtain advice from the Pharmaceutical Benefits Advisory Committee before making such a declaration. Failure to comply with the provisions of this legislative instrument may result in various consequences. While specific offences are not outlined in the text, the National Health Act 1953 provides for penalties for breaches. These penalties could include fines and other civil or criminal sanctions, depending on the nature and severity of the breach. The maximum penalties are not specified in the legislative instrument itself but can be found within the broader context of the National Health Act 1953. It is also important to note that any failure to update records or systems to reflect the cessation of the listed drugs and preparations could lead to administrative and compliance issues, potentially affecting the delivery of healthcare services and the financial management of healthcare budgets.